Background: Quantitative, miniaturized nucleic acid assays and immunoassays can be developed with single microparticles, microfluorometric detection, and intrinsically fluorescent lanthanide chelates in a multiple assay format to decrease reagent consumption, cost, and assay time. We used recombinant Fab fragments to capture and detect free and total prostate-specific antigen (PSA) from serum in a submicroliter volume singleparticle immunoassay. Methods: Genetically engineered thiol-Fab or thiolated monoclonal antibodies (mAbs) were covalently attached onto uniformly sized 60-m maleimide-activated microparticles. Free and total PSA were detected with europium-or terbium-labeled Fab fragments on a single microparticle using a microfluorometer in a time-resolved mode. Results: The detection limit of the free-and total-PSA assays (mean ؉ 3 SD of zero calibrator) was 0.35 g/L, with a total volume of 330 nL per particle. An excellent correlation was found in microparticle and microtiterwell assays for 21 serum samples: slopes for free and total PSA were 1.06 ؎ 0.03 and 1.03 ؎ 0.02, respectively (S yͦx ‫؍‬ 0.084 and 0.057 g/L), with intercepts of 0.013 ؎ 0.018 and 0.013 ؎ 0.017 g/L (R >0.99). Furthermore, the particle-immobilized Fab fragment had a PSA binding capacity 1.5-fold higher than the intact mAb capacity on a single microparticle. Capacity, kinetics, and sensitivity of the Fab fragment and intact mAb assays in the microparticle and microtiter well formats are discussed. Conclusions: With site-specific (cysteine tail) covalent attachment of Fab fragments on a microparticle, subattomole amounts of PSA can be detected quantitatively.
The RecAll prostate-specific antigen (PSA) 1 assay, based entirely on site-specific recombinant Fab fragments for capturing and detecting the analyte, has been demonstrated previously (9 ) . The Fab fragments were sitespecifically labeled with nonfluorescent lanthanide chelates, whose signals were enhanced with fluorescence enhancement solution. The use of intrinsically fluorescent lanthanide chelates allows more compact and rapid assays as well as multiplex assays to be performed because no additional enhancement step is required. We describe here a PSA assay that relies on the use of recombinant Fab fragments, intrinsically fluorescent lanthanide chelates, and porous microparticles as solid support (Fig. 1 ). To detect low PSA concentrations, we used an advanced microscope-based detection system to measure analyte quantitatively. We previously have shown that subattomole quantities of PSA can be detected by this timeresolved fluorescence detection technology (10 ) . For the first time, clinical functionality of this assay concept is demonstrated.
Materials and Methods microparticles
The immunoassays were performed using monosized microparticles purchased from Sintef Applied Chemistry. The particles were polymerized by a swelling method from acrylate/glycidylmethacrylate (3 ). After polymerization, the surface was grafted to contain amino groups (Sintef). The 60-m particles were highly porous, having a total surface area of 85 m 2 /g (measured with BrunauerEmmet-Teller isoterm). More than 95% of the pores were 20 -500 nm in diameter according to the manufacturer.
microparticle coating
The microparticles were coated with specific thiolated monoclonal antibodies (mAbs) or recombinant Fab fragments against PSA (H117-mAb-SH or H117-Fab-SH). The H117-Fab-SH was produced in our laboratories by genetic engineering for insertion of a free cysteine residue at the COOH terminus of the Fd chain (Meretoja et al. and Lamminmäki et al., submitted for publication).
The H117-mAb was thiolated with N-succinimidyl S-acetylthioacetate (SATA; Pierce). SATA was dissolved in dimethyl sulfoxide to a concentration of 4.7 mol/L, and 4 L of this solution was added to a H117-mAb solution in a total volume of 400 L. The H117-mAb solution contained 850 g of intact antibody in a 50 mmol/L phosphate buffer, pH 7.8, containing 1 mmol/L EDTA. This reaction was carried out at room temperature for 30 min. Thiolated mAb was purified from unreacted SATA by NAP-5 and NAP-10 columns (Amersham Pharmacia Biotech). The thiolated mAbs were eluted with 50 mmol/L phosphate buffer, pH 7.8, containing 1 mmol/L EDTA, and concentrated with a Centricon 50 concentrator (Millipore) to ϳ100 L. The latent thiol group was released by the addition of 0.5 mol/L hydroxylamine in 50 mmol/L phosphate buffer, pH 7.5, containing 25 mmol/L EDTA. The number of thiol groups per mAb were quantified with Ellman reagents (Pierce).
The recombinant H117-Fab-SH fragment was stored at 4°C in a 50 mmol/L glycine-Tris buffer, pH 6.0, containing 1 mmol/L dithiothreitol. Before coating, dithiothreitol was removed by NAP-5 and NAP-10 columns with 50 mmol/L phosphate buffer, pH 7.8, containing 25 mmol/L EDTA (buffer A) or 50 mmol/L borate buffer, pH 8.3, containing 5 mmol/L EDTA (buffer B). Immediately after the purification, Tris[2-carboxyethyl]phosphine hydrochloride (Pierce) was added to a concentration of 20 mol/L. The eluted H117-Fab-SH was concentrated with a Centricon 30 concentrator.
Approximately 15 000 amino-grafted particles were activated with 0.5-50 mmol/L N-[⑀-maleimido caproyloxy] sulfosuccinimide ester (EMCS; Pierce) or 0.1-5 mmol/L sulfosuccinimidyl [4-iodoacetyl] aminobenzoate (sulfo-SIAB; Pierce) in 500 L of buffers A and B, respectively. The activation was carried out by end-over-end rotation (Rotamix; Heto Lab Equipment) for 30 -80 min at room temperature. The sulfo-SIAB activation was performed in the dark. The activation solution was removed, and 10 -60 ng of H117-Fab-SH or 115-170 ng of H117-mAb-SH was added to the microparticles. The reaction was mixed in a Rotamix at room temperature overnight (sulfo-SIAB in dark) and stopped by incubation of the particles with 400 L of 0.01 mol/L cysteine in 50 mmol/L phosphate buffer, pH 7.8, in an end-over-end rotation for 2 h at room temperature. Finally the particles Fig. 1 . Principle of the free-and total-PSA assays.
Capture Fab H117-Fab was covalently attached to a porous 60-m particle to a porous 60-m particle through a site-specific thiol group. Europium-labeled 5A10-Fab detected free PSA, and terbium-labeled H50-Fab detected total PSA, including complexed PSA, mainly ␣ 1 -antichymotrypsin (ACT).
were washed four times with 2 mmol/L Tris buffer, pH 7.5, containing 0.1 g/L Tween 20 and stored in the Tris-HCl solution at 4°C.
microparticle binding capacity
The PSA-binding capacities of antibody-coated beads were determined using Eu(III)-labeled free PSA to saturate the surfaces. The assays were performed as described elsewhere (11 ) .
labeling of Fab fragments
The PSA-specific Fab fragments were produced in our laboratories (Meretoja et al. and Lamminmäki et al., submitted for publication). Briefly, the genes coding for Fabs were cloned from hybridoma cells producing corresponding mAbs, and the clones were transferred to pKKtac vector. The Fabs were produced to Escherichia coli periplasmic space and purified using a cation-exchange chromatography column (SP Streamline; Amersham Pharmacia Biotech) and a protein G affinity column (Amersham Pharmacia Biotech). The 5A10-Fab recognizing the free form of PSA was labeled with the europium(III) chelate of 2,2Ј,2Љ,2ٞ-{{6,6Ј-{4Љ-[2-(4-isothiocyanatophenyl)ethyl]1H-pyrazol-1,3-diyl}bis(pyridine)-2,2Ј-diyl} bis(methylenenitrilo)}tetrakis(acetic acid) (chelate I) (12 ) . The H50-mAbs recognizing free and complexed forms of PSA were labeled with the same ligand, using terbium(III) ion. The labeling procedure has been described previously (11 ) . The labeling of the Fab fragments was 4.5 europium or terbium molecules per Fab when determined against Eu(III) and Tb(III) calibrators. The affinity constant of the labeled 5A10-Fab fragment was determined as described previously (9 ) .
assay kinetics
The kinetics of the two-step PSA immunoassays were determined in a total volume of 330 nL/microparticle (20 microparticles/reaction tube) using 67 nL of sample per microparticle at room temperature. The assays were carried out at a PSA concentration of 50 g/L in the assay buffer (Wallac). After incubation with PSA in an endover-end rotation or a vortex-type mixer (Vortex; Scientific Industries), the microparticles were washed three times with 50 mmol/L Tris-HCl, pH 7.8, containing 9 g/L NaCl, 1 g/L Germall II, 5 g/L Tween 40, and 5 g/L Tween 20 (buffer C). In the tracer incubation, 1.5 ng of 5A10-FabEu(III) or 4.5 ng of 5A10-mAb-Eu(III) was incubated in a total volume of 330 nL/particle and washed with buffer C. For detection, the particle suspension was centrifuged, and the particles were pipetted on a Cyclopore tracketched membrane (5 m; Whatman) and dried out through the membrane with a tissue. The quantity of the analyte was measured directly on the surface of the microparticle with a microfluorometer (Wallac) in a timeresolved mode (10 ) . One-step PSA assays were performed as above, but with the analyte and tracers incubated in the same reaction.
The microtiter plate assays were carried out as recommended by the manufacturer (Wallac). Briefly, in the two-step assay, 25 L of PSA calibrator (Dual PSA reagent set; Wallac) was incubated in the assay buffer for 1 h and the tracers for 2 h in total volumes of 125 and 200 L, respectively. Finally, europium ions were dissolved from the chelate into 200 L of the DELFIA enhancement solution (Wallac). The signal was measured with the Victor 1420 multilabel counter (Wallac).
calibration curves
The assay conditions for the calibration curves were as described under "Assay Kinetics". The PSA incubation time was 180 min, and the tracer was incubated with the PSA-bound microparticles for 10 min. Ten replicates were measured for the zero concentration, and 8 replicates were measured for the calibration samples containing analyte. The detection limit of the assays was calculated from the zero calibrator plus 3 SD. Serum samples were a kind gift from Dr. Maciej Kwiatkowski (Kantonspital, Aarau, Switzerland).
Results

antibody immobilization on microparticles
The immunoassay of free and complexed PSA was carried out on 60-m particles coated with PSA-specific H117-mAb or recombinant H117-Fab-SH fragment. To use the same coupling chemistry for both H117-mAb and H117-Fab-SH, the intact antibody was thiolated. Three SH groups were introduced on one H117-mAb molecule. The thiol groups were not thought to interfere the binding capacity of the mAb because a labeling degree higher than 3 is often used in labeling, e.g., fluorophores on antibodies. Previously, we successfully labeled H117-mAb with 12 Eu(III) chelates without impairing the binding activity (13 ) .
Originally, the microparticles carried epoxy groups on the surface as a result of the glycidylmethacrylate copolymer used in the polymerization process. Additional surface modification was made by Sintef to obtain primary amino groups. Two thiol-active linkers, sulfo-SIAB and EMCS, were investigated for optimum loading capacity and assay performance of H117-Fab. Equal Fab fragment-loading capacities were found with both linkers in the Eu(III)-labeled PSA assay when 0.5 mg of sulfo-SIAB and 10 mg of EMCS were used. Because nonspecific binding was increased in the PSA assay of sulfo-SIABactivated microparticles, EMCS activation was used in the final mAb and Fab fragment immobilizations.
The PSA-binding capacities were 1.0 and 1.5 ng on single H117-mAb and H117-Fab microparticles, respectively. Maximum loading of the surface capturing antibodies was achieved when 170 ng of H117-mAb or 50 ng of H117-Fab was used per microparticle. Higher amounts of antibody molecules did not increase the binding of europium-labeled PSA on the particles.
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labeling of Fab fragments
Although site-specific bioconjugation was made possible through recombinant Fab fragment production, the Fab fragments were not labeled through the thiol groups in the current study because one chelate per Fab fragment did not yield satisfactory signals. Fab fragments were labeled through the amino groups, yielding a labeling of 4.5 chelate molecules/Fab molecule for both europium and terbium chelates I. The affinity constant for the labeled 5A10-Fab fragment was calculated to determine whether relatively high labeling had an impact on the PSA-binding efficiency. The assay revealed that the affinity constant of the tracer 5A10-Fab, 2 ϫ 10 9 L/mol, was not significantly different from that of the nonlabeled Fab fragment, 3 ϫ 10 9 L/mol.
kinetics
To increase the speed of the microparticle assay, two mixing systems were investigated, end-over-end mixing and vortex mixing. In end-over-end mixing, the assay solution and the microparticles did not move actively, which was observed visually using a stroboscope. More vigorous vortex mixing enhanced the movement of the microparticles, substantially improving assay speed. In comparison with the end-over-end mixing (two-step assay), kinetics in the one-step PSA assay were approximately fourfold faster (Fig. 2) . Hence, vortex mixing was used in the subsequent PSA assays. The kinetic curve of the PSA incubation with the microparticles in the two-step assay is shown in Fig. 2 . Equilibrium was reached in ϳ160 min. Reaction volume, amount of the tracer molecules, and mixing efficiency were varied to test whether the smaller size of the Fab fragment compared with the mAb had an effect on assay kinetics. No significant kinetic difference was found in the Fab and mAb assays (data not shown). Free PSA was used as a model, but in the assays, complexed PSA should give identical results because the rate was limited by the association rate to the solid-phase antibody as well as the mixing efficiency. The assay kinetics were further studied using different numbers of particles in the same assay volume. Increasing the amount of particles by a factor of 10 decreased the total PSA assay time by the same factor (data not shown).
calibration curves
The sensitivity of an immunoassay is strongly dependent on the ratio of sample to total assay volume. The sample volume was one-fifth of the total volume in all assays performed in this study. Volumes of 200, 330, and 1000 nL/microparticle were investigated to test the effect of total volume on the efficiency in binding PSA. In these assays, Ͼ90% of the analyte was captured. Because no significant difference was found among various assay volumes, the 330-nL volume was chosen for further assays to achieve reasonable assay speed and sensitivity.
The calibration curves and precision profiles at different free-and total-PSA concentrations when the total assay volume was 330 nL/microparticle are shown in Fig.  3 . Eight individual microparticles were detected at each analyte concentration. The assay had excellent linear response, and the detection range was three orders of magnitude. The lower detection limit was 0.35 g/L for both free and total PSA when calculated from the response for the zero calibrator plus 3 SD. The within-run CV was well below 10% for all measured concentrations.
Correlation data for free PSA by the microparticle and the commercial DELFIA microtiter plate assays are illustrated in Fig. 4 . Excellent correlation was found for serum samples. The slopes for the microparticle and microtiter Fig. 2 . Kinetics of binding of PSA to a microparticle in the first step of the two-step single-particle PSA assay (OE) using vortex mixing, and for end-over-end (f) and vortex (F) mixing in the one-step PSA assay.
The assays were performed in a total volume of 330 nL, using 67 nL of PSA calibrator per microparticle. 
Discussion
The multiple microparticle assay is the most common assay principle in clinical analyzers today. Contrary to the multiple microparticle approach, technologies based on single microparticle detection have been implemented successfully for multianalyte bioaffinity assays (1, 2, 13 ) . These technologies provide the full benefits of multiplexing assay systems because of a small and mobile solid phase. Here we demonstrate the clinical feasibility of the single microparticle method in detecting free and total PSA in submicroliter volumes. Previously, intact antibodies were used to demonstrate the functionality of the single microparticle approach (10 ) . To reduce interfering effects of heterophilic antibodies, complement, and rheumatoid factors in these assays, recombinant Fab fragments have been applied in the current single microparticle approach. Fab fragments were used for both capturing and detecting the analyte on the microparticles. The reduced size and the site-specificity of the Fab fragment provided higher surface density than an intact antibody, indicating improved assay performance. The clinical functionality of the single microparticle principle in Fab fragment-based PSA assay was verified with serum samples for the first time.
A prerequisite for detecting any multiple analytes, such as free and total PSA, in submicroliter assay volumes is an advanced labeling technology. Fluorescence-based assays are suitable for simultaneous detection of such multiple targets. The sensitivity of assays performed with prompt fluorescent labels is limited by nonspecific fluorescence and autofluorescence. The practical sensitivity of biological assays can be improved by the use of luminophores with high specific activity and low nonspecific fluorescence, such as luminescent inorganic phosphors (14 ) , cofluorescent chelates (15 ), lanthanide cryptates (16 ) , and lanthanide chelates (10, (17) (18) (19) . We previously have shown that with lanthanide chelates, 1 ϫ 10 4 europium molecules can be detected on a single microparticle (10 ) . To perform a functional assay on a microparticle, we labeled PSA-specific Fab fragments with europium and terbium chelate I. Relatively high labeling of the tracer Fab fragments, 4.5 chelate molecules/Fab molecule, was achieved. One could anticipate that such high labeling would impair the binding efficiencies of the antibody fragments, but the effect was found to be insignificant.
Intact H117-mAbs and H117-Fab fragments were immobilized onto the microparticle by the same thiol-coupling chemistry, enabling a comparison of the PSAbinding capacity of the two antibody surfaces. More available binding sites were found when Fab fragments were immobilized onto a microparticle than when intact mAbs were conjugated because of the smaller size and improved orientation (site-specific conjugation through cysteine residue) of the Fab fragment. We have obtained similar results for microtiter plate PSA assays in which biotinylated capture Fabs or mAbs were immobilized on a streptavidin surface (unpublished data).
The calculated PSA-binding capacity on a microparticle per surface area (1 ng/5 ϫ 10 Ϫ6 m 2 ϭ 2 ϫ 10 Ϫ4 g/m 2 ) was approximately fivefold lower than on a commercial polystyrene microtiter well (130 ng/1.4 ϫ 10 Ϫ4 m 2 ϭ 9 ϫ 10 Ϫ4 g/m 2 ; Wallac) when H117-mAb was immobilized on both surfaces. The microparticle surface area had been estimated with a Brunauer-Emmet-Teller isoterm study by the manufacturer. This method fails to determine whether all of the surface area is available for protein binding. One can readily think that a porous medium containing access-restricted channels decreases the available protein-binding surface. Hence, the calculated surface area is likely to be overestimated, yielding an actual PSA-binding capacity per surface area close to that of a microtiter well. Thus, the idea of using single porous microparticles in clinical immunoassays has a particular interest because the assay volume can be reduced substantially from that of the microtiter plate format because of the mobile and densely packed solid phase. In the commercial DELFIA anti-PSA microtiter plate assay, a total assay volume of 125 L is recommended by the manufacturer. If we consider that both microparticles and microtiter wells hold the same PSA-binding capacity per surface area, the PSA assay could be performed in ϳ1 L without sacrificing any of the assay performance. The volume of a single microparticle is in the order of 100 fL, which can be neglected when calculating a total assay volume because the effect in any practical assay volume is negligible.
The kinetic comparison of labeled Fab fragments and intact antibodies was performed in the single microparticle PSA assay. We varied the amount of tracer molecules, assay volume, and mixing efficiencies in the tracer incubation. Because in the noncompetitive PSA immunoassay the tracer molecule was introduced in an excess into the reaction and the mixing of the reaction was apparently efficient, very similar kinetic behavior was found for both the Fab and mAb (this applies to mAbs recognizing both the free and complexed forms of PSA) assays, indicating that diffusion was not limiting in the current assays. Although no size-dependent kinetic improvement was found with recombinant Fab fragments, the genetic engineering technique is a promising tool to produce antibody fragments with improved on-rate values to increase the speed of an assay. The smaller size, however, becomes extremely important when high surface loading is of interest. With a simple kinetic simulation, one can show that the reaction rate is improved in a linear manner when the concentration of the surface capturing antibody is increased. In a microtiter plate format, we found improved PSA assay kinetics with increasing loading capacity when we used biotinylated Fab fragments (unpublished data). Several studies on porous microparticles have indicated that high loading capacity might not be an ideal approach kinetically. In these experiments, slow assay kinetics were likely to originate from restricted access of molecules into the pores and slow diffusion of molecules inside the pores (20 -22 ) . The use of small recombinant Fab fragments should, however, reduce these effects.
The surface-to-volume ratio of a microparticle assay plays a predominant role in determining the limits of the assay speed, as reported previously (11 ) . A 10-fold increase in the particle amount (and hence, a 10-fold decrease in the surface-to-volume ratio) reduced the time for the PSA assay from 160 to 20 min (total assay volume decreased from 330 to 35 nL). To perform a single-particle PSA assay in 12 min (the saturation time in the commercial DELFIA microtiter plate format), a total assay volume of 20 nL/particle should be used. This volume is ϳ50-fold lower than expected from the surface-to-volume calculations of a microparticle and a microtiter plate. This gives an idea of the magnitude of the kinetic limitation in a densely packed porous solid phase, although the microparticle and microtiter well assay formats cannot be compared fully, mainly because of differences in liquidtransfer efficiencies. We believe that the vortex mixing was very efficient because the motion of the solution and microparticles was rapid when observed with a stroboscope. Hence, the 50-fold difference in the estimated value and experimental data likely originated from the densely packed porous structure and not from a reduced external mass transport. It is difficult to confirm experimentally whether this effect is attributable to the porosity or mass transport because the limited loading capacity of a 60-m compact microparticle does not allow an equal comparison. Attempts have made to overcome the problem of mass transport in porous particles in chromatographic media by using highly porous beads (pore size, 800 nm in diameter) (23 ) . Although some convection occurs in these porous beads, flow around the particles is still preferred (21 ) . Thus, the passage of molecules within the pores is considered to be controlled by diffusion, and no significant improvement in kinetics would be expected if a larger pore size was used.
In terms of kinetics, the single-microparticle approach with volumes Ͻ50 nL is feasible for rapid assays. Without system automation, such a low volume assay is not, however, practical. Today, numerous examples can be found in the literature where microtechnology has been used to make reaction cells, channels, pumps, and detection systems suitable for extremely low-volume assays (24 ) . These technologies should enable the application of instrumentation to the single-microparticle concept.
We obtained excellent linear response and a detection range covering more than three orders of magnitude in the miniature Fab fragment immunoassay of free and total PSA when the analyte was detected on a single microparticle. The microparticle assay and the corresponding DELFIA immunoassay in microtiter plates correlated well when 21 serum samples were studied. In these microparticle assays, subattomole quantities were monitored. Although the clinical utility of the present assay has been verified, further improvements in sensitivity are needed to perform rapid PSA assays using low nanoliter volumes. However, fast analysis could be performed with analytes such as C-reactive protein in the range of clinical interest with the current method. During the past year, we have studied alternative time-resolved fluorescence labels to detect analyte concentrations that could not be monitored with the present labeling technology. Using these labels with higher specific activity, we could achieve an improved detection limit for single microparticles.
